secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001326110-25-000146
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio appoints Bruce Wendel to board of directors effective Dec. 12.
--------------------------------------------------------------------------

- Bruce Wendel appointed independent director effective Dec. 12, 2025; term expires at 2026 annual meeting.
- Background includes Abraxis BioScience (commercialized Abraxane, led Celgene acquisition), Bristol-Myers Squibb.
- Receives $50k annual cash retainer plus initial stock option with $300k Black-Scholes value, vesting 1/3 annually over 3 years.
- Previously served on boards of GT BioPharma and Verastem.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000146/0001326110-25-000146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000146/ibrx-20251210.htm
  HTML page:      https://secwatch.observer/filing/0001326110-25-000146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer